Compare UAN & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAN | ABCL |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2008 | 2020 |
| Metric | UAN | ABCL |
|---|---|---|
| Price | $121.56 | $5.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.40 |
| AVG Volume (30 Days) | 49.7K | ★ 8.5M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | ★ 61.98 | 10.91 |
| EPS | ★ 4.72 | N/A |
| Revenue | ★ $606,038,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21.85 |
| P/E Ratio | $26.32 | ★ N/A |
| Revenue Growth | 15.36 | ★ 160.56 |
| 52 Week Low | $81.18 | $1.98 |
| 52 Week High | $139.50 | $6.52 |
| Indicator | UAN | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 66.96 |
| Support Level | $120.05 | $5.34 |
| Resistance Level | $139.42 | $5.63 |
| Average True Range (ATR) | 4.66 | 0.43 |
| MACD | -0.98 | 0.05 |
| Stochastic Oscillator | 10.32 | 87.28 |
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.